Opening a new window
The treatment of Female Sexual Dysfunction

Female Sexual Disorder (FSD) is a problem of which the magnitude and implication is frequently underestimated. In the US alone, more than 30 percent of all women have little or no desire in sex. Only some women suffering from FSD seek professional help for it. Yet, there are millions of women for whom FSD is a serious problem.

The pharmaceutical industry is diligently looking for solutions, but has not been very successful to date. However, the experimental results of Lybrido were considered promising. Lybrido is the first medicine with both a central and a peripheral effect.

Read more >>

10-12-2008 EB announces positive results from its’ study The influence of testosterone combined with a PDE5-inhibitor on cognitive, affective, and physiological sexual functioning in women suffering from sexual dysfunction.

13-11-2008 EB today treated the first subject in it’s study Lybridos PoC: a double blind, randomized, cross-over placebo controlled pilot study to investigate the subjective and physiological efficacy and safety of Lybridos in SSRI female subjects with Female Sexual Dysfunction

10-10-2008 EB announces it has received ethical committee approval to start it’s phase 2B study Lybridos PoC: a double blind, randomized, cross-over placebo controlled pilot study to investigate the subjective and physiological efficacy and safety of Lybridos in SSRI female subjects with Female Sexual Dysfunction. This study will recruit 8 women and will be conducted at EB’s research facility in Almere.

18-07-2008 EB announces positive results from its’ study The clitoral photoplethysmograph: a new way of assessing genital arousal in women.

26-05-2008 EB today treated the first subject in study Lybrido(s)@Home: A double blind, randomized, cross-over placebo controlled study to investigate the subjective and physiological efficacy and safety of Lybrido and Lybridos in the domestic setting in healthy female subjects with Female Sexual Dysfunction

16-05-2008 EB announces it has received ethical committee approval to start Phase 2B study Lybrido(s)@Home: A double blind, randomized, cross-over placebo controlled study to investigate the subjective and physiological efficacy and safety of Lybrido and Lybridos in the domestic setting in healthy female subjects with Female Sexual Dysfunction. This study will recruit 60 women and will be conducted both at home as well as at EB’s research facility.

24-12-2007 EB announces positive results from its’ study The influence of testosterone combined with a PDE5-inhibitor on cognitive, affective, and physiological sexual functioning in women suffering from sexual dysfunction.

23-11-2007 EB announces positive results from its’ pilot study on Childhood Sexual Abuse, Selective Attention for Sexual Cues and the Effects of Testosterone with or without Vardenafil on Physiological Sexual Arousal in Women with Sexual Dysfunction.

07-09-2007 EB today treated the first subject in the phase 2b study A double blind randomized placebo-controlled cross-over study to validate the distinction between women with different levels of attention and valence direction for erotic stimuli, in relation to genital and subjective sexual arousal in healthy female subjects and healthy female subjects with Female Sexual Dysfunction

06-09-2007 EB announces it has received ethical committee approval to start a phase 2B study A double blind randomized placebo-controlled cross-over study to validate the distinction between women with different levels of attention and valence direction for erotic stimuli, in relation to genital and subjective sexual arousal in healthy female subjects and healthy female subjects with Female Sexual Dysfunction. The study will recruit 70 women and will be conducted at EB’s research facility in Almere.

07-05-2007 EB today treated the first subject in its study of objective measurement systems in FSD research. This phase 2 study - The clitoral photoplethysmograph: a new way of assessing genital arousal in women will recruit 30 women, and will be conducted at EB’s research facility in Almere

06-02-2007 EB today treated the first subject in study Functional neuro-anatomy of sexual arousal during treatment of testosterone combined with sildenafil in healthy female subjects with FSD.

5-02-2007 EB announces it has received ethical committee approval to start study a phase 2 study to investigate Functional neuro-anatomy of sexual arousal during treatment of testosterone combined with sildenafil in healthy female subjects with FSD. The study, to be conducted at the AMC (Amsterdam Medical Center) the Netherlands, will recruit 30 women

03-11-2006 EB today treated the first subject in a phase 1 study of The influence of testosterone combined with a PDE5-inhibitor on cognitive, affective, and physiological sexual functioning in women suffering from sexual dysfunction.

30-08-2006 EB announces it has received ethical committee approval to start a Phase 1 study in healthy female volunteers to investigate The influence of testosterone combined with a PDE5-inhibitor on cognitive, affective, and physiological sexual functioning in women suffering from sexual dysfunction. The study will recruit 28 women and will be conducted in EB’s facility (in Almere).

21-07-2004 EB today treated the first subject in its pilot study Childhood Sexual Abuse, Selective Attention for Sexual Cues and the Effects of Testosterone with or without Vardenafil on Physiological Sexual Arousal in Women with Sexual Dysfunction

16-06-2004 EB today announced that it has received ethical committee approval to start a pilot study into female sexual dysfunction arising from sexual abuse: Childhood Sexual Abuse, Selective Attention for Sexual Cues and the Effects of Testosterone with or without Vardenafil on Physiological Sexual Arousal in Women with Sexual Dysfunction. The study will recruit 13 women and will be conducted in EB’s facility (in Almere ).